Company

Product

Description

Indication

Status

Phase I

Cstone Pharmaceuticals Inc., of Suzhou, China

CS-1003

Anti-PD-1 antibody

Advanced tumors

Preliminary efficacy data from bridging study showed, of 16 evaluable patients, 7 remained on treatment with a median treatment duration of 21.3 weeks; at 60 mg, 1 patients with esophageal squamous cell carcinoma and 1 patient with uterine leiomyosarcoma had confirmed partial response (PR) per RECIST v1.1; at 200 mg, 1 patient with laryngeal squamous cell carcinoma was determined to be in PR awaiting confirmation

Phase II

Xortx Therapeutics Inc., of Calgary, Alberta and Teijin Pharma Ltd., of Tokyo

TMX-049

Non-purine xanthine oxidase inhibitor tablet

Diabetic nephropathy

TMX-049 met primary endpoint, significantly decreasing serum uric acid and urinary albumin proteinuria; no new safety concerns observed

Phase III

Innovent Biologics Inc., of Suzhou, China

IBI-301

Rituximab biosimilar

Diffuse large B-cell lymphoma

2 trials have shown the pharmacokinetic equivalence of IBI-301 with rituximab in CD20+ B-cell lymphoma patients who achieved complete response (CR)/CR unconfirmed after treatment, and the safety and tolerance similarity of both drugs

Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y. and Sanofi SA, of Paris

Dupixent (dupilumab)

IL-13 receptor antagonist; IL-4 receptor antagonist

Nasal polyps

Highlighted publication in The Lancet of detailed positive results from 2 in adults with recurring severe chronic rhinosinusitis with nasal polyps despite previous treatment with surgery and/or systemic corticosteroids.


Notes

For more information about individual companies and/or products, see Cortellis.

No Comments